✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key Takeaways — HCG for Post-Cycle Therapy (PCT)
- HCG re-stimulates the testes after exogenous androgens have suppressed pituitary LH output. It does not restart the pituitary itself — that recovery requires SERM-based PCT (clomiphene, tamoxifen) after HCG.
- Standard PCT-only HCG protocol: 500–1,500 IU subcutaneously every other day for 7–14 days, beginning when androgen levels have cleared, followed by 4–6 weeks of clomiphene + tamoxifen.
- HCG should not be used in isolation as PCT. Sustained high-dose HCG without the SERM phase desensitises Leydig cells and delays HPTA recovery rather than accelerating it.
- Pre-cycle bloodwork (total testosterone, free T, LH, FSH, estradiol-sensitive) and post-recovery bloodwork (8–12 weeks after PCT completion) define whether the protocol worked.
- HCG is a banned substance for athletes in most testing organisations (WADA, UFC, NCAA). Anyone subject to testing should be aware that pharmaceutical HCG and “PCT” use are detected on standard panels.
- For TRT-adjunct vs PCT context see our HCG buying guide 2026; for general dosing math see our HCG dose protocol guide.
What Happens to the HPTA After a Cycle
The hypothalamic-pituitary-testicular axis (HPTA) responds to exogenous androgens by reducing endogenous LH and FSH output. Within 1–4 weeks of starting a steroid cycle, pituitary LH output is near zero, intratesticular testosterone falls 95%+, and Leydig and Sertoli cells become quiescent. The duration and depth of suppression depends on the compounds used, doses, cycle length, and individual variation.
When the cycle ends and exogenous androgens clear, the HPTA needs to restart. Three things have to happen, in this order:
- Pituitary LH/FSH output resumes. The hypothalamic GnRH pulse generator and pituitary gonadotrophs need to recover. This is the rate-limiting step in most cases.
- Leydig and Sertoli cells respond to LH/FSH. If the testes have been quiescent for many months, they need a few weeks of LH stimulation to regain maximal output.
- Spermatogenesis resumes. Sertoli-cell-dependent; trails the testosterone recovery by 8–12 weeks because spermatogenic cycles are slow.
HCG — a long-acting LH analogue — accelerates step 2 by directly stimulating the testes, while step 1 catches up. SERMs (clomiphene, tamoxifen) accelerate step 1 by blocking estrogen-mediated negative feedback at the hypothalamus and pituitary. The combined sequence is HCG first, then SERMs.
The Standard HCG-Then-SERM Protocol
| Phase | Drug | Dose | Duration |
|---|---|---|---|
| HCG kick-start | HCG SC | 500–1,500 IU EOD | 7–14 days |
| SERM phase 1 | Clomiphene oral | 50 mg/day | 14 days |
| SERM phase 2 | Clomiphene oral (taper) + tamoxifen | 25 mg/day clomiphene + 20 mg/day tamoxifen | 14–28 days |
| Recovery taper | Tamoxifen alone | 10 mg/day → off | 7 days |
Total recovery window from end-of-cycle to off-PCT is 6–8 weeks. Bloodwork at 4 and 8 weeks post-PCT defines whether the HPTA has restarted. Total testosterone within reference range with detectable LH and FSH is the recovery endpoint.
Timing — When to Start HCG
The trickiest decision in PCT is when to begin HCG. The rule:
- HCG should begin when exogenous androgens have cleared from circulation, not while they are still active. If active androgens are present, HCG simply adds to them and contributes nothing to recovery.
- For short-ester cycles (testosterone propionate, trenbolone acetate): start HCG 3–4 days after last injection.
- For medium-ester cycles (testosterone enanthate/cypionate, trenbolone enanthate): start HCG 10–14 days after last injection.
- For long-ester cycles (testosterone undecanoate, nandrolone decanoate): start HCG 3–4 weeks after last injection.
- For oral-only cycles (anavar, dianabol): start HCG 1–3 days after last dose.
SERMs begin after the HCG phase ends. Starting SERMs while HCG is still being administered is unhelpful — clomiphene and tamoxifen work by removing estrogen negative feedback from the hypothalamus, but if HCG is providing testicular drive directly, the central feedback signal is irrelevant.
Why HCG-Only PCT Doesn’t Work
A naive PCT plan is “just use HCG until everything recovers”. This fails because:
- HCG suppresses pituitary LH via classical negative feedback (the pituitary cannot distinguish exogenous HCG from endogenous LH). Sustained high-dose HCG keeps the pituitary asleep just as testosterone did during the cycle.
- HCG desensitises Leydig cells at sustained doses above ~1,500 IU/day. The receptor downregulates; testicular response to subsequent LH stimulation is blunted.
- The hypothalamic GnRH pulse generator requires removal of estrogen feedback to restart. HCG-driven aromatisation actually elevates estradiol, suppressing GnRH further.
The 7–14 day HCG window in the standard protocol is short and at modest doses for exactly these reasons. The Leydig cells are restarted; then HCG stops; SERMs take over for the central recovery.
Common error: “blast-and-cruise” HCG
Some users on long cycles run HCG continuously through the cycle and into PCT at high doses (2,000–4,000 IU/week) on the theory that it prevents testicular shutdown entirely. The mechanism is real (HCG does maintain Leydig-cell viability during testosterone administration), but the practical effect at high doses is sustained Leydig-cell hyperstimulation, elevated estradiol, and downregulated LH receptors. By the time the cycle ends and PCT begins, the testes are no easier to restart than they would have been on testosterone alone, and may be harder. Standard TRT-adjunct doses (250 IU 3× weekly) are appropriate for testicular preservation; PCT-restart doses (500–1,500 IU EOD for 7–14 days) are appropriate for the kick-start phase. Continuous HCG at PCT-restart-level doses is not.
Bloodwork: What to Measure and When
| Time | Markers | What you’re looking for |
|---|---|---|
| Pre-cycle | Total T, free T, LH, FSH, E2 sensitive, prolactin, SHBG, lipid panel, LFTs | Baseline; defines what “recovery” means for this individual |
| End of HCG phase | Total T, E2 sensitive | Confirms Leydig cells are responsive; check for elevated E2 |
| Mid-SERM phase | Total T, LH, FSH | Confirms central recovery is starting |
| 4 wk post-PCT | Total T, free T, LH, FSH, E2 | Recovery indicator |
| 8–12 wk post-PCT | Full panel; semen analysis if fertility planning | Final recovery confirmation |
Recovery is defined by total testosterone within the reference range with detectable LH and FSH, and (where fertility matters) sperm parameters returning to baseline. Persistent LH/FSH suppression after 12 weeks of post-PCT bloodwork suggests the HPTA has not recovered fully — at which point the user is in “post-cycle hypogonadism” territory and should consult an endocrinologist.
Adjuncts: Aromatase Inhibitors and Prolactin Management
Two classes of adjunct may be appropriate during HCG PCT:
- Aromatase inhibitor (anastrozole 0.25–0.5 mg EOD): used if estradiol rises above the user’s tolerance during the HCG phase. HCG-driven testicular testosterone is aromatised in adipose and other tissues; some users develop temporary E2-related symptoms (water retention, mood, gynaecomastia tenderness). See our anastrozole (Anastronat).
- Cabergoline / bromocriptine: relevant only for cycles that included 19-nor compounds (nandrolone, trenbolone), where prolactin elevation is a known side effect. HCG itself does not raise prolactin meaningfully.
Most users on testosterone-only or testosterone + low-androgenic-cycle compounds do not need either adjunct during PCT.
Where to Buy HCG and PCT Supplies
MedsBase ships the standard PCT bench:
- HUCOG 5000IU · HUCOG 10000IU — workhorse HCG vials.
- Eutrig HP 5000IU · ZyHCG HP 10000IU — alternative WHO-GMP brands.
- Clomisign (clomiphene 50 mg) — SERM phase 1 + 2.
- PCT Stack (Clomisign + Tamoxilon) — bundled clomiphene + tamoxifen at a discount.
- Bacteriostatic water — for HCG reconstitution; 30-day stability.
All orders covered by the Reshipment Assurance Policy. Discreet shipping worldwide; statements show the processor, not MedsBase.
Frequently Asked Questions
Is HCG necessary for every PCT?
No. For short cycles (≤8 weeks) at modest doses, SERM-only PCT (clomiphene + tamoxifen) often works adequately. HCG becomes more useful for longer cycles (12+ weeks), high-dose cycles, or cycles featuring strongly suppressive compounds (trenbolone, nandrolone) where the testes have been quiescent for many months.
Can I run HCG during my cycle to avoid testicular atrophy?
Yes — at low TRT-adjunct doses (250 IU SC 2–3× weekly), on-cycle HCG preserves testicular volume and intratesticular testosterone without significantly desensitising Leydig cells. This is different from PCT-restart dosing. See our HCG buying guide for the on-cycle vs PCT dose distinction.
What’s the difference between HCG and the SERMs?
HCG mimics LH and acts directly on the testes. SERMs (clomiphene, tamoxifen) act on the hypothalamus and pituitary by blocking estrogen receptors, removing the negative feedback that keeps LH suppressed. HCG accelerates testicular response; SERMs accelerate central recovery. They are complementary, not substitutable.
Should I run an aromatase inhibitor with HCG?
Run E2 bloodwork during the HCG phase. If estradiol is within reference range and the user is asymptomatic, no aromatase inhibitor is needed. If estradiol is elevated or symptoms develop (water retention, gynaecomastia tenderness, mood), low-dose anastrozole (0.25–0.5 mg EOD) is appropriate. Avoid suppressing E2 below the reference range — it impairs recovery and produces its own symptom set.
Why not just take HCG every day for a month?
Sustained high-dose HCG desensitises Leydig-cell receptors and elevates estradiol via aromatisation. The result is that testicular response to subsequent LH stimulation is blunted, central recovery is delayed by elevated estradiol, and PCT takes longer overall. The 7–14 day window at moderate doses is the empirical sweet spot.
Can I do PCT without bloodwork?
You can run the protocol without bloodwork, but you will not know whether it worked. “I feel fine” is not a recovery endpoint — many men with persistent post-cycle HPTA suppression feel adequate but have suppressed labs. Bloodwork at 4 and 8–12 weeks post-PCT is the only reliable way to confirm recovery.
What if my testosterone is still suppressed 12 weeks after PCT?
This is post-cycle hypogonadism. Options include: (1) repeating an extended SERM phase, (2) switching to clomiphene monotherapy long-term (a recognised treatment for secondary hypogonadism), or (3) accepting TRT. An endocrinology consultation at this point is appropriate. The longer suppression persists, the lower the chance of full natural recovery.
Is PCT relevant to TRT-adjunct HCG users?
No. TRT users are not coming “off” — they are on testosterone indefinitely. The PCT framework applies to users who are ending an androgen cycle and want their natural HPTA to restart. TRT-adjunct HCG (preserving testicular function during continuous testosterone administration) is a separate use case at lower doses. See our HCG for men: TRT and beyond for that context.
Medical Disclaimer: This article is educational and is not a substitute for personalised medical advice. PCT protocols described here reflect mainstream practice in the bodybuilding and TRT-clinic communities and are not FDA-approved indications for HCG, clomiphene, or tamoxifen for non-cycling adult men. Use of these medicines outside their approved indications carries clinical risks including persistent hypogonadism, fertility impact, and visual disturbances (clomiphene). Anyone considering this protocol should review their personal history with a qualified clinician and run pre- and post-protocol bloodwork. HCG is also a banned substance in most athletic testing organisations.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.